Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report

Assunta Bianco, Massimiliano Mirabella, Matteo Lucchini, Paola Del Giacomo, Chiara De Fino, Viviana Nociti

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

10 Citazioni (Scopus)

Abstract

The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have a reduced antibody immune response to viral neoantigens. A relative sparing of mucosal-associated lymphoid tissues (MALT) could be responsible for IgA response in our patient.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaMultiple Sclerosis and Related Disorders
Volume44
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • COVID-19
  • IgA
  • IgG
  • Ocrelizumab
  • Serology

Fingerprint Entra nei temi di ricerca di 'Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report'. Insieme formano una fingerprint unica.

Cita questo